AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03790371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: vaginal misoprostol prior IUD insertion
Study NCT03790371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: vaginal placebo tablet prior IUD insertion
Study NCT02208089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial Photorefractive Keratectomy (TransPRK)
Description: Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
Study NCT02208089 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Collagen Cross-Linking (CXL)
Description: Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)
Study NCT02208089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Collagen Cross-Linking (CXL)
Description: Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)
Study NCT05186792 — intervention group
Intervention type: OTHER
Intervention: Test:mycoplasma
Description: Retrospective analysis of records of recruits to a previous mycoplasma study.
Study NCT02132806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery with biomaterial mp3 + bracket
Study NCT02132806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery with biomaterial mp3
Study NCT02132806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Study NCT03062163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resveratrol lipoic Acid
Description: Transdermal patch loaded with resveratrol and lipoic acid
Study NCT03062163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Transdermal patch loaded with normal saline
Study NCT02040077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer + Fluency
Study NCT02040077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Only
Study NCT02040077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study NCT00216138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
Study NCT00216138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 po bid, days 1-14
Study NCT00216138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premedication
Description: Dexamethasone and antiemetic premedication
Study NCT02279108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: One injection, 2.5 milligrams per patient, intradermal use
Study NCT02279108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotope
Description: One injection, 20 MBq techntium99, intradermal use
Study NCT02279108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotope
Description: One injection, 20 MBq techntium99, intradermal use
Study NCT02768831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.
Study NCT02768831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
Study NCT01128309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction Intervention
Description: eight week group program, plus daily homework practice
Study NCT01128309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control intervention
Description: weekly group meetings for eight weeks, plus daily homework practice
Study NCT05455008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely-delivered health coaching intervention
Description: Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
Study NCT03840343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose
Description: Two MSC infusions of 2.5x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
Study NCT00574509 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131Iodine-Anti-B1 Radioimmunotherapy
Description: Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
Study NCT00574509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM
Description: Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran
Study NCT00004984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Insulin
Description: Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.
Study NCT00004984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Close Observation
Description: Study visits every 6 months including an oral glucose tolerance test
Study NCT03840343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
Description: Two MSC infusions of 5.0x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
Study NCT02593708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Study NCT02593708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02593708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Study NCT01762839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-Dose IV Oritavancin Diphosphate
Description: Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
Study NCT01762839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
Study NCT01762839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.
Study NCT02593708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01537055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin-based sequential therapy
Description: levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
Study NCT01537055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin-based triple therapy for 10 days
Description: lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
Study NCT02458547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8\~1.0
Study NCT02458547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Total intravenous anesthesia with propofol target controlled infusion
Study NCT02458547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Spinal anesthesia with 0.5% bupivacaine
Study NCT02483130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: N-Acetylcysteine
Description: Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
Study NCT00500604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/hydrochlorothiazide
Description: 150/12.5mg tablet and 300/12.5mg tablet
Study NCT00500604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan/hydrochlorothiazide
Description: 80/12.5mg tablet and 160/12.5mg tablet
Study NCT00500604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12.5 mg administered orally, once daily in the morning
Study NCT02961049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel and dentin etched
Description: Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
Study NCT02483130 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
Study NCT00500604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 12.5 mg administered orally, once daily in the morning
Study NCT01875042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation
Study NCT01875042 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: Sham Transcutaneous electrical nerve stimulation
Study NCT03777124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects receive SHR-1210 intravenous every 2 weeks
Study NCT03777124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Subjects receive Apatinib orally every day
Study NCT03777124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Subjects receive Pemetrexed intravenous every 3 weeks
Study NCT03777124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: subjects receive carboplatin intravenous every 3 weeks
Study NCT03517995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane Administration
Description: 1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
Study NCT03517995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: 1 capsule (placebo) taken two times per day (2 capsules total).
Study NCT03517995 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Surgery
Description: The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
Study NCT03517995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Surgery
Description: The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
Study NCT04526470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Dose level -2: 200 mg PO once daily / Dose level -1: 200 mg PO once daily / Dose level 0: 250 mg PO once daily / Dose level 1: 300 mg PO once daily
Study NCT04526470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Dose level -2: 60 mg/m2 IV on day 1, 8, and 15 / Dose level -1: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 0: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 1: 70 mg/m2 IV on day 1, 8, and 15
Study NCT01694277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: 12 mg/kg/day
Study NCT01694277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg/day
Study NCT01627444 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ear acupuncture
Description: Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
Study NCT01627444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ear acupuncture
Description: Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
Study NCT02674425 — intervention group
Intervention type: DEVICE
Intervention: Dark Adaptometer
Study NCT02525939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalcetrapib
Description: Cholesterol Ester Transfer Protein inhibitor
Study NCT02525939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets
Study NCT02506686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem i.v.
Study NCT04287088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: A shared decision making
Description: Based on prostate cancer risk calculation (age, usage of 5-ARI medication, baseline PSA, IMPROD bpMRI Likert, prostate volume) a shared decision making whether to perform prostate biopsies or not
Study NCT04154319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Vaccination
Description: Mothers assigned to this arm participated in educational/behavior change sessions to promote HPV vaccination among their unvaccinated 9-12 year old daughters
Study NCT04154319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Eating
Description: Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels
Study NCT02002468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test result sent by letter
Study NCT02002468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test result conveyed by general practitioners
Study NCT02002468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test result conveyed by general practitioners
Study NCT00762996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens
Study NCT00762996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: contact lens
Study NCT00514228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: * Starting dose: 37.5 mg 3 x 12.5 mg capsule~* Reduced dose: 25 mg 2 x 12.5 mg capsule
Study NCT02723890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tyto Device
Study NCT02944565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03659058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silymarin
Description: silymarin 140 three times daily
Study NCT03784898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw for future biomarker analysis
Description: Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).
Study NCT02320097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Foot pressure measurement
Description: Description of the foot pressure measurement:~The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions.
Study NCT03847727 — intervention group
Intervention type: DRUG
Intervention: BR as Maintenance
Description: Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
Study NCT00868894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 medium concentration
Description: Topical ocular application
Study NCT00868894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 high concentration
Description: Topical ocular application
Study NCT00868894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical ocular application
Study NCT00868894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.005% latanoprost
Description: Topical ocular application
Study NCT03659058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic Acid 500
Study NCT03659058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidants
Description: Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
Study NCT03659058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.6
Study NCT03659058 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FOLLOW UP
Description: follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
Study NCT03659058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOLLOW UP
Description: follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
Study NCT05918627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil mesylate
Description: Pharmaceutical form: capsule; Route of administration: oral
Study NCT05918627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: capsule; Route of administration: oral
Study NCT01536548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin drawing
Description: Mark direction and angle for cannulation with a pencil on the skin
Study NCT01536548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No skin drawing
Description: Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
Study NCT03772418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream Base
Description: The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
Study NCT03772418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomegrante and Ginkgo biloba group
Description: The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
Study NCT00780286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer based lubricating liquid
Description: 5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
Study NCT00780286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moi-Stir
Description: 2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
Study NCT00558532 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
Study NCT06320548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-residue diet
Description: Patients received clear explanations, practical schemes, and a list of allowed foods, tailored to fit individual needs.
Study NCT06320548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Free diet
Description: Patients had free diet.
Study NCT01113034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAS181 dry powder, formulation F02
Description: 10 mg delivered dose DAS181 in clear HPMC #3 Capsules
Study NCT01113034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Respitose ML006 (DMV-Fonterra)
Description: Lactose monohydrate
Study NCT03755232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: scFOS
Description: Fossence™ (short chain Fructo-oligosaccharides (scFOS)